Cytoplasmic staining of c-erbB-2 is not associated with the presence of detectable c-erbB-2 mRNA in breast cancer specimens

被引:0
作者
Taylor, SL
Platt-Higgins, A
Rudland, PS
Winstanley, JHR
Barraclough, R
机构
[1] Univ Liverpool, Sch Biol Sci, Canc Tissue Bank Res Ctr, Liverpool L69 7ZB, Merseyside, England
[2] Univ Liverpool, Sch Biol Sci, Mol Med Grp, Liverpool L69 7ZB, Merseyside, England
[3] Univ Liverpool, Dept Surg, Liverpool L69 7ZB, Merseyside, England
关键词
D O I
10.1002/(SICI)1097-0215(19980518)76:4<459::AID-IJC2>3.0.CO;2-Q
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The cell-surface receptor tyrosine kinase protein c-erbB-2 is immunocytochemically detected as membrane staining on the surface of cancer cells in 20-30% of cases of breast cancer, and its presence has been associated with poor prognosis for the patient. However, there have been numerous reports of immunocytochemical staining for c-erbB-2 solely in the cytoplasm of some normal and tumour specimens with frequently used anti-sera, and the presence of such staining has been difficult to interpret. It is not known for certain that cytoplasmic c-erbB-2 staining is an artefact of the immunocytochemical procedures used. Thus, mRNA for c-erbB-2 has been quantified in tumours exhibiting only cytoplasmic staining or varying levels of membrane staining using a sensitive, competitive PCR method. Whereas abundant levels of c-erbB-2 mRNA are found in tumours exhibiting membrane staining for c-erbB-2 and these levels correlate with the percentage of tumour cells showing membranous staining for c-erbB-2, the level of c-erbB-2 mRNA in tumours displaying only cytoplasmic staining is no higher than in c-erbs-2-negative specimens. (C) 1998 Wiley-Liss, Inc.
引用
收藏
页码:459 / 463
页数:5
相关论文
共 20 条
[1]   COMPARATIVE EXPRESSION OF FIBROBLAST GROWTH-FACTOR MESSENGER-RNAS IN BENIGN AND MALIGNANT BREAST DISEASE [J].
ANANDAPPA, SY ;
WINSTANLEY, JHR ;
LEINSTER, S ;
GREEN, B ;
RUDLAND, PS ;
BARRACLOUGH, R .
BRITISH JOURNAL OF CANCER, 1994, 69 (04) :772-776
[2]  
BERGER MS, 1988, CANCER RES, V48, P1238
[3]   ANALYSIS OF CERBB2 EXPRESSION USING A PANEL OF 6 COMMERCIALLY AVAILABLE ANTIBODIES [J].
BUSMANIS, I ;
FELEPPA, F ;
JONES, A ;
MCGRATH, KM ;
REED, R ;
COLLINS, J ;
RUSSELL, I ;
BEGLEY, CG .
PATHOLOGY, 1994, 26 (03) :261-267
[4]  
DEPOTTER CR, 1989, HISTOPATHOLOGY, V15, P351
[5]   THE NEU-ONCOGENE PROTEIN AS A PREDICTIVE FACTOR FOR HAEMATOGENOUS METASTASES IN BREAST-CANCER PATIENTS [J].
DEPOTTER, CR ;
BEGHIN, C ;
MAKAR, AP ;
VANDEKERCKHOVE, D ;
ROELS, HJ .
INTERNATIONAL JOURNAL OF CANCER, 1990, 45 (01) :55-58
[6]   THE NEU-ONCOGENE - MORE THAN A PROGNOSTIC INDICATOR [J].
DEPOTTER, CR .
HUMAN PATHOLOGY, 1994, 25 (12) :1264-1268
[7]   THE SUBCELLULAR-LOCALIZATION OF THE NEU PROTEIN IN HUMAN NORMAL AND NEOPLASTIC-CELLS [J].
DEPOTTER, CR ;
QUATACKER, J ;
MAERTENS, G ;
VANDAELE, S ;
PAUWELS, C ;
VERHOFSTEDE, C ;
EECHAUTE, W ;
ROELS, H .
INTERNATIONAL JOURNAL OF CANCER, 1989, 44 (06) :969-974
[8]  
FIELD JK, 1992, ANTICANCER RES, V12, P613
[9]   EARLY STAGES OF ABSORPTION OF INJECTED HORSERADISH PEROXIDASE IN PROXIMAL TUBULES OF MOUSE KIDNEY - ULTRASTRUCTURAL CYTOCHEMISTRY BY A NEW TECHNIQUE [J].
GRAHAM, RC ;
KARNOVSKY, MJ .
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 1966, 14 (04) :291-+
[10]   EXPRESSION OF THE C-ERBB-2 PROTEIN IN NORMAL AND TRANSFORMED-CELLS [J].
GULLICK, WJ ;
BERGER, MS ;
BENNETT, PLP ;
ROTHBARD, JB ;
WATERFIELD, MD .
INTERNATIONAL JOURNAL OF CANCER, 1987, 40 (02) :246-254